Regulation of oncogenic KRAS signaling via a novel KRAS-integrin-linked kinase-hnRNPA1 regulatory loop in human pancreatic cancer cells

P. C. Chu, M. C. Yang, S. K. Kulp, S. B. Salunke, L. E. Himmel, C. S. Fang, A. M. Jadhav, Y. S. Shan, C. T. Lee, M. D. Lai, L. A. Shirley, Tanios Bekaii-Saab, C. S. Chen

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Integrin-linked kinase (ILK) is a mediator of aggressive phenotype in pancreatic cancer. On the basis of our finding that knockdown of either KRAS or ILK has a reciprocal effect on the other's expression, we hypothesized the presence of an ILK-KRAS regulatory loop that enables pancreatic cancer cells to regulate KRAS expression. This study aimed to elucidate the mechanism by which this regulatory circuitry is regulated and to investigate the translational potential of targeting ILK to suppress oncogenic KRAS signaling in pancreatic cancer. Interplay between KRAS and ILK and the roles of E2F1, c-Myc and heterogeneous nuclear ribonucleoprotein as intermediary effectors in this feedback loop was interrogated by genetic manipulations through small interfering RNA/short hairpin RNA knockdown and ectopic expression, western blotting, PCR, promoter-luciferase reporter assays, chromatin immunoprecipitation and pull-down analyses. In vivo efficacy of ILK inhibition was evaluated in two murine xenograft models. Our data show that KRAS regulated the expression of ILK through E2F1-mediated transcriptional activation, which, in turn, controlled KRAS gene expression via hnRNPA1-mediated destabilization of the G-quadruplex on the KRAS promoter. Moreover, ILK inhibition blocked KRAS-driven epithelial-mesenchymal transition and growth factor-stimulated KRAS expression. The knockdown or pharmacological inhibition of ILK suppressed pancreatic tumor growth, in part, by suppressing KRAS signaling. These studies suggest that this KRAS-E2F1-ILK-hnRNPA1 regulatory loop enables pancreatic cancer cells to promote oncogenic KRAS signaling and to interact with the tumor microenvironment to promote aggressive phenotypes. This regulatory loop provides a mechanistic rationale for targeting ILK to suppress oncogenic KRAS signaling, which might foster new therapeutic strategies for pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)3897-3908
Number of pages12
JournalOncogene
Volume35
Issue number30
DOIs
StatePublished - Jul 28 2016
Externally publishedYes

Fingerprint

Pancreatic Neoplasms
Small Interfering RNA
integrin-linked kinase
Heterogeneous-Nuclear Ribonucleoproteins
G-Quadruplexes
Phenotype
Epithelial-Mesenchymal Transition
Tumor Microenvironment
Chromatin Immunoprecipitation
Luciferases
Heterografts
Transcriptional Activation
Intercellular Signaling Peptides and Proteins
Western Blotting
Pharmacology
Gene Expression
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Chu, P. C., Yang, M. C., Kulp, S. K., Salunke, S. B., Himmel, L. E., Fang, C. S., ... Chen, C. S. (2016). Regulation of oncogenic KRAS signaling via a novel KRAS-integrin-linked kinase-hnRNPA1 regulatory loop in human pancreatic cancer cells. Oncogene, 35(30), 3897-3908. https://doi.org/10.1038/onc.2015.458

Regulation of oncogenic KRAS signaling via a novel KRAS-integrin-linked kinase-hnRNPA1 regulatory loop in human pancreatic cancer cells. / Chu, P. C.; Yang, M. C.; Kulp, S. K.; Salunke, S. B.; Himmel, L. E.; Fang, C. S.; Jadhav, A. M.; Shan, Y. S.; Lee, C. T.; Lai, M. D.; Shirley, L. A.; Bekaii-Saab, Tanios; Chen, C. S.

In: Oncogene, Vol. 35, No. 30, 28.07.2016, p. 3897-3908.

Research output: Contribution to journalArticle

Chu, PC, Yang, MC, Kulp, SK, Salunke, SB, Himmel, LE, Fang, CS, Jadhav, AM, Shan, YS, Lee, CT, Lai, MD, Shirley, LA, Bekaii-Saab, T & Chen, CS 2016, 'Regulation of oncogenic KRAS signaling via a novel KRAS-integrin-linked kinase-hnRNPA1 regulatory loop in human pancreatic cancer cells', Oncogene, vol. 35, no. 30, pp. 3897-3908. https://doi.org/10.1038/onc.2015.458
Chu, P. C. ; Yang, M. C. ; Kulp, S. K. ; Salunke, S. B. ; Himmel, L. E. ; Fang, C. S. ; Jadhav, A. M. ; Shan, Y. S. ; Lee, C. T. ; Lai, M. D. ; Shirley, L. A. ; Bekaii-Saab, Tanios ; Chen, C. S. / Regulation of oncogenic KRAS signaling via a novel KRAS-integrin-linked kinase-hnRNPA1 regulatory loop in human pancreatic cancer cells. In: Oncogene. 2016 ; Vol. 35, No. 30. pp. 3897-3908.
@article{4b370d8e7def458a93195309678f3e28,
title = "Regulation of oncogenic KRAS signaling via a novel KRAS-integrin-linked kinase-hnRNPA1 regulatory loop in human pancreatic cancer cells",
abstract = "Integrin-linked kinase (ILK) is a mediator of aggressive phenotype in pancreatic cancer. On the basis of our finding that knockdown of either KRAS or ILK has a reciprocal effect on the other's expression, we hypothesized the presence of an ILK-KRAS regulatory loop that enables pancreatic cancer cells to regulate KRAS expression. This study aimed to elucidate the mechanism by which this regulatory circuitry is regulated and to investigate the translational potential of targeting ILK to suppress oncogenic KRAS signaling in pancreatic cancer. Interplay between KRAS and ILK and the roles of E2F1, c-Myc and heterogeneous nuclear ribonucleoprotein as intermediary effectors in this feedback loop was interrogated by genetic manipulations through small interfering RNA/short hairpin RNA knockdown and ectopic expression, western blotting, PCR, promoter-luciferase reporter assays, chromatin immunoprecipitation and pull-down analyses. In vivo efficacy of ILK inhibition was evaluated in two murine xenograft models. Our data show that KRAS regulated the expression of ILK through E2F1-mediated transcriptional activation, which, in turn, controlled KRAS gene expression via hnRNPA1-mediated destabilization of the G-quadruplex on the KRAS promoter. Moreover, ILK inhibition blocked KRAS-driven epithelial-mesenchymal transition and growth factor-stimulated KRAS expression. The knockdown or pharmacological inhibition of ILK suppressed pancreatic tumor growth, in part, by suppressing KRAS signaling. These studies suggest that this KRAS-E2F1-ILK-hnRNPA1 regulatory loop enables pancreatic cancer cells to promote oncogenic KRAS signaling and to interact with the tumor microenvironment to promote aggressive phenotypes. This regulatory loop provides a mechanistic rationale for targeting ILK to suppress oncogenic KRAS signaling, which might foster new therapeutic strategies for pancreatic cancer.",
author = "Chu, {P. C.} and Yang, {M. C.} and Kulp, {S. K.} and Salunke, {S. B.} and Himmel, {L. E.} and Fang, {C. S.} and Jadhav, {A. M.} and Shan, {Y. S.} and Lee, {C. T.} and Lai, {M. D.} and Shirley, {L. A.} and Tanios Bekaii-Saab and Chen, {C. S.}",
year = "2016",
month = "7",
day = "28",
doi = "10.1038/onc.2015.458",
language = "English (US)",
volume = "35",
pages = "3897--3908",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "30",

}

TY - JOUR

T1 - Regulation of oncogenic KRAS signaling via a novel KRAS-integrin-linked kinase-hnRNPA1 regulatory loop in human pancreatic cancer cells

AU - Chu, P. C.

AU - Yang, M. C.

AU - Kulp, S. K.

AU - Salunke, S. B.

AU - Himmel, L. E.

AU - Fang, C. S.

AU - Jadhav, A. M.

AU - Shan, Y. S.

AU - Lee, C. T.

AU - Lai, M. D.

AU - Shirley, L. A.

AU - Bekaii-Saab, Tanios

AU - Chen, C. S.

PY - 2016/7/28

Y1 - 2016/7/28

N2 - Integrin-linked kinase (ILK) is a mediator of aggressive phenotype in pancreatic cancer. On the basis of our finding that knockdown of either KRAS or ILK has a reciprocal effect on the other's expression, we hypothesized the presence of an ILK-KRAS regulatory loop that enables pancreatic cancer cells to regulate KRAS expression. This study aimed to elucidate the mechanism by which this regulatory circuitry is regulated and to investigate the translational potential of targeting ILK to suppress oncogenic KRAS signaling in pancreatic cancer. Interplay between KRAS and ILK and the roles of E2F1, c-Myc and heterogeneous nuclear ribonucleoprotein as intermediary effectors in this feedback loop was interrogated by genetic manipulations through small interfering RNA/short hairpin RNA knockdown and ectopic expression, western blotting, PCR, promoter-luciferase reporter assays, chromatin immunoprecipitation and pull-down analyses. In vivo efficacy of ILK inhibition was evaluated in two murine xenograft models. Our data show that KRAS regulated the expression of ILK through E2F1-mediated transcriptional activation, which, in turn, controlled KRAS gene expression via hnRNPA1-mediated destabilization of the G-quadruplex on the KRAS promoter. Moreover, ILK inhibition blocked KRAS-driven epithelial-mesenchymal transition and growth factor-stimulated KRAS expression. The knockdown or pharmacological inhibition of ILK suppressed pancreatic tumor growth, in part, by suppressing KRAS signaling. These studies suggest that this KRAS-E2F1-ILK-hnRNPA1 regulatory loop enables pancreatic cancer cells to promote oncogenic KRAS signaling and to interact with the tumor microenvironment to promote aggressive phenotypes. This regulatory loop provides a mechanistic rationale for targeting ILK to suppress oncogenic KRAS signaling, which might foster new therapeutic strategies for pancreatic cancer.

AB - Integrin-linked kinase (ILK) is a mediator of aggressive phenotype in pancreatic cancer. On the basis of our finding that knockdown of either KRAS or ILK has a reciprocal effect on the other's expression, we hypothesized the presence of an ILK-KRAS regulatory loop that enables pancreatic cancer cells to regulate KRAS expression. This study aimed to elucidate the mechanism by which this regulatory circuitry is regulated and to investigate the translational potential of targeting ILK to suppress oncogenic KRAS signaling in pancreatic cancer. Interplay between KRAS and ILK and the roles of E2F1, c-Myc and heterogeneous nuclear ribonucleoprotein as intermediary effectors in this feedback loop was interrogated by genetic manipulations through small interfering RNA/short hairpin RNA knockdown and ectopic expression, western blotting, PCR, promoter-luciferase reporter assays, chromatin immunoprecipitation and pull-down analyses. In vivo efficacy of ILK inhibition was evaluated in two murine xenograft models. Our data show that KRAS regulated the expression of ILK through E2F1-mediated transcriptional activation, which, in turn, controlled KRAS gene expression via hnRNPA1-mediated destabilization of the G-quadruplex on the KRAS promoter. Moreover, ILK inhibition blocked KRAS-driven epithelial-mesenchymal transition and growth factor-stimulated KRAS expression. The knockdown or pharmacological inhibition of ILK suppressed pancreatic tumor growth, in part, by suppressing KRAS signaling. These studies suggest that this KRAS-E2F1-ILK-hnRNPA1 regulatory loop enables pancreatic cancer cells to promote oncogenic KRAS signaling and to interact with the tumor microenvironment to promote aggressive phenotypes. This regulatory loop provides a mechanistic rationale for targeting ILK to suppress oncogenic KRAS signaling, which might foster new therapeutic strategies for pancreatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=84955324811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955324811&partnerID=8YFLogxK

U2 - 10.1038/onc.2015.458

DO - 10.1038/onc.2015.458

M3 - Article

C2 - 26616862

AN - SCOPUS:84955324811

VL - 35

SP - 3897

EP - 3908

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 30

ER -